ATE203402T1 - Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz - Google Patents

Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz

Info

Publication number: ATE203402T1
Authority: AT; Austria
Prior art keywords: dementia; dimethylphenyl; pyrrolidinyl; acetamide; oxo
Prior art date: 1991-05-02

Application number

AT92107421T

Other languages

English (en)

Inventor

Eiichi Otomo

Yoshiyuki Takasu

Tadashi Shiotani

Kazuo Hasegawa

Akira Honma

Original Assignee

Daiichi Seiyaku Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-02

Filing date

1992-04-30

Publication date

2001-08-15

1992-04-30 Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co

2001-08-15 Application granted granted Critical

2001-08-15 Publication of ATE203402T1 publication Critical patent/ATE203402T1/de

Links

206010012289 Dementia Diseases 0.000 title abstract 3
NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 title abstract 2
208000024891 symptom Diseases 0.000 abstract 2
206010000117 Abnormal behaviour Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
208000013677 cerebrovascular dementia Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000007423 decrease Effects 0.000 abstract 1
230000003247 decreasing effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000004970 emotional disturbance Effects 0.000 abstract 1
230000006870 function Effects 0.000 abstract 1
230000003340 mental effect Effects 0.000 abstract 1
230000008450 motivation Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Materials For Medical Uses (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicinal Preparation (AREA)

AT92107421T 1991-05-02 1992-04-30 Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz ATE203402T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP22981891		1991-05-02
JP22981991		1991-05-02

Publications (1)

Publication Number	Publication Date
ATE203402T1 true ATE203402T1 (de)	2001-08-15

Family

ID=26529012

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92107421T ATE203402T1 (de)	1991-05-02	1992-04-30	Verwendung von n-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamid zur behandlung von demenz

Country Status (21)

Country	Link
US (1)	US5886023A (de)
EP (1)	EP0515866B1 (de)
KR (1)	KR100310590B1 (de)
AT (1)	ATE203402T1 (de)
AU (2)	AU1595492A (de)
CA (1)	CA2067614C (de)
CZ (1)	CZ281170B6 (de)
DE (1)	DE69231955T2 (de)
DK (1)	DK0515866T3 (de)
ES (1)	ES2160097T3 (de)
GR (1)	GR3036970T3 (de)
HU (1)	HU224689B1 (de)
IE (1)	IE921377A1 (de)
IL (1)	IL101738A (de)
MX (1)	MX9202058A (de)
NO (1)	NO312813B1 (de)
PT (1)	PT515866E (de)
RU (1)	RU2070042C1 (de)
SG (1)	SG49650A1 (de)
SK (1)	SK279285B6 (de)
TW (1)	TW199096B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2267375A1 (en) *	1996-10-01	1998-04-09	Mitsunobu Yoshii	Mitochondrial membrane stabilizer
AU8131198A (en)	1997-07-15	1999-02-10	Daiichi Pharmaceutical Co., Ltd.	Prophylactic or therapeutic agent for amnesia
IT1312107B1 (it) *	1999-05-14	2002-04-04	Umberto Cornelli	Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
CA2374921A1 (en) *	1999-05-31	2000-12-07	Shigeo Watabe	Neuronal death inhibitors
US20040077709A1 (en) *	1999-05-31	2004-04-22	Daiichi Pharmaceutical Co., Ltd.	Neuronal death inhibitors
US6376489B1 (en) *	1999-12-23	2002-04-23	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
US6423739B1 (en) *	2000-02-23	2002-07-23	Daiichi Pharmaceutical Co., Ltd.	Method for aiding cerebral recovery following neurodegeneration
GB0004297D0 (en) *	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6348489B1 (en) *	2000-04-11	2002-02-19	Daiichi Pharmaceutical Co., Ltd.	Method of treating traumatic brain injury and other neuronal disorders
US7608636B2 (en) *	2000-12-28	2009-10-27	Hamilton Pharmaceuticals, Inc.	Medicines for treatment and prevention of neurogenic pain
ES2311537T3 (es) *	2001-08-22	2009-02-16	Hamilton Pharmaceuticals, Inc.	Utilizacion de nefiracetam en el tratamiento de la neurodegeneracion postquemica.
US20060241144A1 (en) *	2005-04-20	2006-10-26	Albert Cha	Method for treating apathy syndrome
US7972633B2 (en) *	2007-02-07	2011-07-05	Applied Cognitive Sciences, LLC	Nutritional supplements for healthy memory and mental function
RU2327480C1 (ru) *	2007-05-23	2008-06-27	Виктор Иванович Рощин	Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения больных с дементным синдромом
JP5917148B2 (ja) *	2008-10-16	2016-05-11	ザジョーンズホプキンズユニバーシティＴｈｅＪｏｈｎｓＨｏｐｋｉｎｓＵｎｉｖｅｒｓｉｔｙ	認知機能を改善するための方法および組成物
EA037187B1 (ru) *	2010-02-09	2021-02-17	Дзе Джонс Хопкинс Юниверсити	Способ и композиция для лечения когнитивного расстройства
WO2014078568A1 (en)	2012-11-14	2014-05-22	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US11160785B2 (en)	2013-03-15	2021-11-02	Agenebio Inc.	Methods and compositions for improving cognitive function
US10806717B2 (en)	2013-03-15	2020-10-20	The Johns Hopkins University	Methods and compositions for improving cognitive function
MX384391B (es)	2015-05-22	2025-03-14	Agenebio Inc	Composiciones farmacéuticas de levetiracetam de liberación extendida.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE864269A (fr) *	1977-03-03	1978-06-16	Parke Davis & Co	Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) *	1979-06-13	1986-10-01	Nattermann A & Cie	Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) *	1981-03-11	1983-05-24	Barry Reisberg	Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) *	1987-08-20	1994-12-07	キッセイ薬品工業株式会社	抗痴呆剤
IT1231477B (it) *	1989-07-12	1991-12-07	Sigma Tau Ind Farmaceuti	(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

1992
- 1992-04-29 CZ CS921306A patent/CZ281170B6/cs not_active IP Right Cessation
- 1992-04-29 SK SK1306-92A patent/SK279285B6/sk unknown
- 1992-04-29 CA CA002067614A patent/CA2067614C/en not_active Expired - Lifetime
- 1992-04-30 EP EP92107421A patent/EP0515866B1/de not_active Expired - Lifetime
- 1992-04-30 NO NO19921724A patent/NO312813B1/no unknown
- 1992-04-30 MX MX9202058A patent/MX9202058A/es not_active IP Right Cessation
- 1992-04-30 DK DK92107421T patent/DK0515866T3/da active
- 1992-04-30 SG SG1996002798A patent/SG49650A1/en unknown
- 1992-04-30 ES ES92107421T patent/ES2160097T3/es not_active Expired - Lifetime
- 1992-04-30 AT AT92107421T patent/ATE203402T1/de not_active IP Right Cessation
- 1992-04-30 PT PT92107421T patent/PT515866E/pt unknown
- 1992-04-30 RU SU5011760/14A patent/RU2070042C1/ru not_active IP Right Cessation
- 1992-04-30 DE DE69231955T patent/DE69231955T2/de not_active Expired - Lifetime
- 1992-04-30 IL IL10173892A patent/IL101738A/en active IP Right Grant
- 1992-04-30 HU HU9201477A patent/HU224689B1/hu not_active IP Right Cessation
- 1992-05-01 KR KR1019920007433A patent/KR100310590B1/ko not_active Expired - Fee Related
- 1992-05-01 AU AU15954/92A patent/AU1595492A/en not_active Abandoned
- 1992-05-01 TW TW081103420A patent/TW199096B/zh active
- 1992-07-01 IE IE137792A patent/IE921377A1/en not_active IP Right Cessation
1995
- 1995-05-22 US US08/447,054 patent/US5886023A/en not_active Expired - Fee Related
- 1995-11-08 AU AU37745/95A patent/AU697936B2/en not_active Ceased
2001
- 2001-10-22 GR GR20010401840T patent/GR3036970T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
GR3036970T3 (en)	2002-01-31
AU697936B2 (en)	1998-10-22
DE69231955T2 (de)	2002-04-04
CA2067614C (en)	2002-07-30
AU3774595A (en)	1996-03-07
CA2067614A1 (en)	1992-11-03
PT515866E (pt)	2001-11-30
SK279285B6 (sk)	1998-09-09
AU1595492A (en)	1992-11-05
EP0515866B1 (de)	2001-07-25
NO312813B1 (no)	2002-07-08
HUT62790A (en)	1993-06-28
KR920021143A (ko)	1992-12-18
IE921377A1 (en)	1992-11-04
TW199096B (de)	1993-02-01
US5886023A (en)	1999-03-23
IL101738A0 (en)	1992-12-30
HU224689B1 (hu)	2005-12-28
NO921724L (no)	1992-11-03
DE69231955D1 (de)	2001-08-30
ES2160097T3 (es)	2001-11-01
CS130692A3 (en)	1992-11-18
NO921724D0 (no)	1992-04-30
CZ281170B6 (cs)	1996-07-17
HK1002153A1 (en)	1998-07-31
IL101738A (en)	1999-01-26
SG49650A1 (en)	1998-06-15
HU9201477D0 (en)	1992-07-28
RU2070042C1 (ru)	1996-12-10
DK0515866T3 (da)	2001-09-24
EP0515866A1 (de)	1992-12-02
KR100310590B1 (ko)	2001-12-28
MX9202058A (es)	1993-03-01

Legal Events

Date	Code	Title
2002-01-15	UEP	Publication of translation of european patent specification
2006-07-15	EEIH	Change in the person of patent owner
2009-01-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69231955D1 (de)	2001-08-30	Verwendung von N-(2,6-Dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamid zur Behandlung von Demenz
ATE206919T1 (de)	2001-11-15	Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE69200675D1 (de)	1994-12-22	Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
ATE184792T1 (de)	1999-10-15	2-bromomelatonin zur behandlung von schlafstörungen
DE69310065D1 (de)	1997-05-28	Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
DE69422450D1 (de)	2000-02-10	Chinoline oder Chinazolin-Derivate und deren Verwendung zur Herstellung eines Medikaments für die Behandlung von Osteoporose
NO167913C (no)	1991-12-27	Analogifremgangsmaate for fremstilling av terapeutisk aktive triamine
ATE269066T1 (de)	2004-07-15	Kombinationstherapie zur prophylaxe und/oder behandlung von gutartiger prostatischer hyperplasie
ATE179892T1 (de)	1999-05-15	Verwendung von lipid-gebundener glykoaminoglykanen zur behandlung der rheumatoider arthritis
DE69400799D1 (de)	1996-11-28	Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
NO179472C (no)	1996-10-16	Opplösning omfattende benzoxoniumklorid for behandling av kontaktlinser, og anvendelse derav til konservering av kontaktlinser og legemidler for öynene
ATE193450T1 (de)	2000-06-15	Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenbrüchen
NO921525L (no)	1992-04-21	L-alfa-glyserofosforyl-d-myo-inositol for behandling av perifere nervelidelser og hjernelidelser
DE69326188D1 (de)	1999-10-07	Verwendung von N-Acylderivaten von Aminoalkoholen zur Herstellung eines Arzneimittels zur Behandlung von neurogenen endoneuralen Ödemen der peripheren Nerven
DE69300037D1 (de)	1995-02-09	Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE68901172D1 (de)	1992-05-14	(-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ATE148344T1 (de)	1997-02-15	Verwendung von 15-dehydroxy-16-oxoprostaglandin bei der behandlung von allergischen erkrankungen
DK0826373T3 (da)	2003-09-29	Forebyggende middel mod postoperativ astigmatisme
DE69200948D1 (de)	1995-02-02	Verwendung von Benzimidazolin-2-oxo-1-Carbonsäurederivaten bei der Behandlung organischer Gehirnerkrankungen.
ATE476188T1 (de)	2010-08-15	Medikament zur prävention und behandlung von familiärer amyloid polyneuropathie
DE3585312D1 (de)	1992-03-12	Anwendung von 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyrido(1,2-a)pyrimidin-3-carboxamid zur vorbeugung und behandlung von gastrointestinalschaeden.
AT400224B (de)	1995-11-27	Mittel zur behandlung und pflege von hufen
ATE91234T1 (de)	1993-07-15	Verwendung von dimetylheptylphenylbutanoylethanolamin bei der behandlung von hyperuricemie.